Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordana Jovic

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Statistics in Medicine|December 21, 2010
An exact method for analysis following a two-stage phase II cancer clinical trialGordana Jovic, John Whitehead
Clinical Breast Cancer|May 27, 2008
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB)Antonio Frassoldati, Valentina Guarneri, Federico Piacentini, et al.
Acta Oto-Laryngologica|December 17, 2008
Middle turbinate preservation versus middle turbinate resection in endoscopic surgical treatment of nasal polyposisDaniele Marchioni, Matteo Alicandri-Ciufelli, Francesco Mattioli, et al.
Statistical Methods in Medical Research|June 20, 2018
Marginal structural models with dose-delay joint-exposure for assessing variations to chemotherapy intensityCarlo Lancia, Cristian Spitoni, Jakob Anninga, et al.
International Journal of Colorectal Disease|December 1, 2005
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapyLorena Losi, Gabriele Luppi, Margherita Gavioli, et al.
Blood|July 27, 2007
Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profilesGiovanni Emilia, Mario Luppi, Patrizia Zucchini, et al.
The Oncologist|July 25, 2008
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient managementValentina Guarneri, Simona Giovannelli, Guido Ficarra, et al.
International Journal of Radiation Oncology, Biology, Physics|April 21, 2007
Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapyFederica Bertolini, Carmelo Bengala, Luisa Losi, et al.
European Urology|January 9, 2018
Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 TrialAntoine Kass-Iliyya, Gordana Jovic, Claire Murphy, et al.
International Journal of Radiation Oncology, Biology, Physics|November 14, 2008
Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancerFederica Bertolini, Silvana Chiara, Carmelo Bengala, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Statistics in Medicine|December 21, 2010
An exact method for analysis following a two-stage phase II cancer clinical trialGordana Jovic, John Whitehead
Clinical Breast Cancer|May 27, 2008
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB)Antonio Frassoldati, Valentina Guarneri, Federico Piacentini, et al.
Acta Oto-Laryngologica|December 17, 2008
Middle turbinate preservation versus middle turbinate resection in endoscopic surgical treatment of nasal polyposisDaniele Marchioni, Matteo Alicandri-Ciufelli, Francesco Mattioli, et al.
Statistical Methods in Medical Research|June 20, 2018
Marginal structural models with dose-delay joint-exposure for assessing variations to chemotherapy intensityCarlo Lancia, Cristian Spitoni, Jakob Anninga, et al.
International Journal of Colorectal Disease|December 1, 2005
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapyLorena Losi, Gabriele Luppi, Margherita Gavioli, et al.
Blood|July 27, 2007
Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profilesGiovanni Emilia, Mario Luppi, Patrizia Zucchini, et al.
The Oncologist|July 25, 2008
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient managementValentina Guarneri, Simona Giovannelli, Guido Ficarra, et al.
International Journal of Radiation Oncology, Biology, Physics|April 21, 2007
Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapyFederica Bertolini, Carmelo Bengala, Luisa Losi, et al.
European Urology|January 9, 2018
Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 TrialAntoine Kass-Iliyya, Gordana Jovic, Claire Murphy, et al.
International Journal of Radiation Oncology, Biology, Physics|November 14, 2008
Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancerFederica Bertolini, Silvana Chiara, Carmelo Bengala, et al.
Pageof 2